RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
Grether U, Foxton RH, Gruener S, Korn C, Kimbara A, Osterwald A, Zirwes E, Uhles S, Thoele J, Colé N, Rogers-Evans M, Röver S, Nettekoven M, Martin RE, Adam JM, Fingerle J, Bissantz C, Guba W, Alker A, Szczesniak AM, Porter RF, Toguri TJ, Revelant F, Poirier A, Perret C, Winther L, Caruso A, Fezza F, Maccarrone M, Kelly MEM, Fauser S, Ullmer C.
Grether U, et al. Among authors: korn c.
Front Pharmacol. 2024 Jul 12;15:1426446. doi: 10.3389/fphar.2024.1426446. eCollection 2024.
Front Pharmacol. 2024.
PMID: 39070793
Free PMC article.